- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.07. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 14.07.2025 | 1.074 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 14.07.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 14.07.2025ISIN NameDK0061031895 SCANDION... ► Artikel lesen | |
| 14.07. | XFRA 8VY: AUSSETZUNG/SUSPENSION | 216 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSCANDION ONC. DK-... ► Artikel lesen | |
| 25.06. | Scandion Oncology A/S: Delisting of the shares of Scandion Oncology - last day of trading July 11, 2025 | 263 | GlobeNewswire (Europe) | In accordance with Nasdaq Stockholm AB's decision, following application from the liquidator of Scandion Oncology, the shares of Scandion Oncology will be delisted from Nasdaq First North Growth Market.... ► Artikel lesen | |
| 25.06. | The observation status for Scandion Oncology A/S is updated | 204 | GlobeNewswire | On February 27, 2025, the shares in Scandion Oncology A/S (the "Company") were given observation status with reference to information that the Company's board of directors would, if a partnership... ► Artikel lesen | |
| 25.06. | Scandion Oncology A/S: Scandion Oncology has applied for delisting of the company's shares from Nasdaq First North Growth Market | 215 | GlobeNewswire (Europe) | The liquidator of Scandion Oncology (the "Company") has today submitted an application for delisting of the Company's shares from Nasdaq First North Growth Market. The last day of trading in the Company's... ► Artikel lesen | |
| SCANDION ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 27.03. | Scandion Oncology A/S: Scandion Oncology Announces Results of Annual General Meeting | 219 | GlobeNewswire (Europe) | The Annual General Meeting 2025 of Scandion Oncology A/S in liquidation (the "Company") was held on 27 March 2025 at 2:00 p.m.
All proposals were adopted in accordance with the notice.As such, the Company... ► Artikel lesen | |
| 13.03. | The observation status for Scandion Oncology A/S is updated | 286 | GlobeNewswire | On February 27, 2025, the shares and equity rights in Scandion Oncology A/S (the "Company") were given observation status with reference to information that the Company's board of directors would... ► Artikel lesen | |
| 13.01. | Scandion Oncology A/S: Scandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer | 247 | GlobeNewswire (Europe) | Scandion Oncology, an innovative drug efflux pump inhibition company using biomodulation capability to revert drug resistance, announces final data from CORIST trial part 1, 2 and 3. In this phase I/II... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 72,20 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,340 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 29,900 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 84,35 | 0,00 % | Kymera Therapeutics stock price target raised to $103 from $70 at RBC Capital | ||
| PRAXIS PRECISION MEDICINES | 280,40 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,400 | 0,00 % | Cathie Wood's ARK sells Tesla stock, buys Coinbase and Recursion Pharmaceuticals | ||
| EDGEWISE THERAPEUTICS | 20,940 | 0,00 % | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | BOULDER, Colo., Dec. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen | |
| IMMUNOME | 22,030 | 0,00 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| IMMUNOVANT | 27,540 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| CG ONCOLOGY | 40,080 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates | Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)Demonstrated... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 81,98 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| JYONG BIOTECH | 4,780 | 0,00 % | Jyong Biotech Ltd.: Jyong Biotech Responds to Share Price and Volume Movement | New Taipei City, Taiwan, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech") notes the recent fluctuation in its share price and the increased trading... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 63,35 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| VERA THERAPEUTICS | 53,80 | 0,00 % | Vera Therapeutics stock price target raised to $66 by BofA Securities | ||
| BICARA THERAPEUTICS | 18,320 | 0,00 % | Mizuho initiates Bicara Therapeutics stock coverage with Neutral rating |
Das Unternehmen SCANDION ONCOLOGY A/S kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,001 Euro.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SCANDION ONCOLOGY A/S finden Sie auf Wallstreet Online.